Vernalis shares slide after FDA turn thumbs down on their latest XR cold med
Five years ago Vernalis and Tris Pharma came up with a plan to develop a portfolio of branded cold meds, using Tris’ extended-release tech to tweak existing medications and turn them into an easier-to-use formulation. That worked on the first try, producing an FDA approval for Tuzistra XR — codeine polistirex and chlorpheniramine polistirex — in the fall of 2015. But the partners ran into a hitch today, with the FDA throwing the red flag on their second try.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.